Iovance Biotherapeutics, Inc. IOVA Business Segments — Sales & Marketing
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingAndMarketingExpense.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s business segments — sales & marketing.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s business segments — sales & marketing?
- Iovance Biotherapeutics, Inc. (IOVA) reported business segments — sales & marketing of $15.12M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s business segments — sales & marketing changed year-over-year?
- Iovance Biotherapeutics, Inc.'s business segments — sales & marketing increased by 13.2% year-over-year, from $13.36M to $15.12M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s business segments — sales & marketing?
- Over 2 years (2023 to 2025), Iovance Biotherapeutics, Inc.'s business segments — sales & marketing has grown at a 58.8% compound annual growth rate (CAGR), from $21.38M to $53.87M.
- What does business segments — sales & marketing mean?
- This represents the costs incurred to promote, distribute, and sell the company's products to healthcare providers and institutions. It is a key indicator of the company's commercialization strategy and its efforts to capture market share.